Insmed Incorporated (INSM) Guidance & Earnings Results

On 2026-08-06 Insmed Incorporated raised guidance: "FY2026 BRINSUPRI revenue raised to $1.25-1.40B from at least $1B; FY2026 ARIKAYCE revenue reiterated $450-470M; peak revenue estimate raised to >$14B (BRINSUPRI >$7B, TPIP >$6B, ARIKAYCE…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

INSMInsmed IncorporatedFollow INSM — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 20.4B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 29 Oct, in 5 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
6 Aug 26	Raised	FY2026 BRINSUPRI revenue raised to $1.25-1.40B from at least $1B; FY2026 ARIKAYCE revenue reiterated $450-470M; peak revenue estimate raised to >$14B (BRINSUPRI >$7B, TPIP >$6B, ARIKAYCE >$1B). · full year
7 May 26	Reaffirmed	BRINSUPRI FY2026 revenue guidance at least $1B; ARIKAYCE FY2026 revenue guidance $450-470M · full year
19 Feb 26	Raised	FY2026 BRINSUPRI revenue at least $1B; ARIKAYCE $450-470M · full year
30 Oct 25	Raised	2025 ARIKAYCE revenue guidance raised to $420-430M from prior range · full year
7 Aug 25	Reaffirmed	FY2025 global ARIKAYCE revenue guidance $405-425 million · full year

Insmed Incorporated — questions

What guidance did Insmed Incorporated give?: On 2026-08-06: "FY2026 BRINSUPRI revenue raised to $1.25-1.40B from at least $1B; FY2026 ARIKAYCE revenue reiterated $450-470M; peak revenue estimate raised to >$14B (BRINSUPRI >$7B, TPIP >$6B, ARIKAYCE >$1B)."
When does Insmed Incorporated report earnings?: Insmed Incorporated's next earnings report is expected on 2026-10-29.

Every figure on this page comes from Insmed Incorporated's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.